NCT05547035

Brief Summary

To evaluate, over a period of six months, the links between physiological data collected such as electrodermal activity (or Galvanic Skin Response), motor activity measured by accelerometer, heartbeat measured by photoplestimograph and the clinical evaluation performed by the physician, in patients suffering from major depression disorder.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for not_applicable major-depressive-disorder

Timeline
Completed

Started Sep 2017

Longer than P75 for not_applicable major-depressive-disorder

Geographic Reach
1 country

11 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 5, 2017

Completed
4.8 years until next milestone

First Submitted

Initial submission to the registry

July 1, 2022

Completed
3 months until next milestone

First Posted

Study publicly available on registry

September 21, 2022

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2025

Completed
Last Updated

March 5, 2024

Status Verified

March 1, 2024

Enrollment Period

7.8 years

First QC Date

July 1, 2022

Last Update Submit

March 4, 2024

Conditions

Outcome Measures

Primary Outcomes (3)

  • Comparison of change in MADRS ( Montgomery-Asberg Depression Rating Scale) total score with physiological measurements.

    * Change in central rater Montgomery-Asberg Depression Rating Scale (MADRS) total score and comparison with changes in physiological measurements such as activity, emotional arousal, heart rate, heart rate variability, breathing rate and sleep. * The Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each of the 10 items is rated on a scale of 0 to 6, with differing descriptors for each item. These individual item scores are added together to form a total score, which can range between 0 (low severity of depressive symptoms) and 60 points (high severity of depressive symptoms), higher score indicating poorer health outcomes. The MADRS provides a measure of the overall level of depression.

    Baseline, Month1, Month 2, Month 3, Month 4, Month 5, Month 6

  • Comparison of change in HAD (Hospital Anxiety and Depression) total score with physiological measurements.

    * Change in Hospital Anxiety and Depression total score and comparison with changes in physiological measurements such as activity, emotional arousal, heart rate, heart rate variability, breathing rate and sleep. * The Hospital Anxiety and Depression Scale used for measuring anxiety Scored on a scale of 0-21 (higher score more anxiety) and for measuring depression Scored on a scale of 0-21 (higher score more depression).

    Baseline, Month1, Month 2, Month 3, Month 4, Month 5, Month 6

  • Comparison of change in CGI (Clinical Global Impression) scale with physiological measurements.

    * Change in CGI scale and comparison with changes in physiological measurements such as activity, emotional arousal, heart rate, heart rate variability, breathing rate and sleep. * The Clinical Global Impression Scale (CGI-s), is a widely administered clinician rated scale that assesses the subject overall illness severity and the degree of improvement from the initial assessment. Illness severity is rated on a 1-7 scale where 1 corresponds to "Normal, Not at All Ill", 2 is "Borderline Mentally Ill", the anchor for 3 is "Mildly Ill", the anchor for 4 is "Moderately Ill", 5 is "Markedly Ill", 6 is "Severely Ill", and 7 is "Among the Most Extremely Ill Patients".The degree of improvement is rated on a 1-7 scale where 1 corresponds to "Very Much Improved", 2 is "Much Improved", the anchor for 3 is "Minimally Improved", the anchor for 4 is "No Change", 5 is "Minimally Worse", 6 is "Much Worse", and 7 is "Very Much Worse".

    Baseline, Month1, Month 2, Month 3, Month 4, Month 5, Month 6

Study Arms (1)

Wearable monitor collected phydiological measurements

EXPERIMENTAL

This is a single arm study with a wearable monitor that collects physiological measures (falling in the categories physical activity, heart rate, heart rate variability, breathing rate and sleep) 24/7 in ambulatory.

Behavioral: Patient follow-up of depression

Interventions

All patients who agree to participate in the study are diagnosed by their GP/Psychiatrist with a diagnostic assessment instrument called DSM-5. Participants visit their GPs/Psychiatrists at baseline, month 1, month 2, month 3, month 4, month 5 and month 6. At each visit, the GPs/Psychiatrists: * assess the depression severity by using MADRS scale * assess the severity of illness at time of assessment compared with start of treatment by using CGI-S measures * the patient complete the self-administered questionnaire of HAD scale that measures the symptoms of anxiety and depression.

Wearable monitor collected phydiological measurements

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient able to give written informed consent, - Presenting a major depressive episode defined according to DSM V criteria, - Presenting a MADRS score ≥ 20 - Able to understand all study procedures and follow-up

You may not qualify if:

  • \- Inability to wear the wearable monitor for the duration of the study (6 months)
  • Patient with a severe medical condition at the discretion of the investigator (neurological, rheumatological, etc.)
  • Resistant depression
  • Chronic depression, dysthymia
  • Depression with psychotic features not congruent with mood, schizophrenia disorder
  • Depression with catatonic features
  • Substance use disorder in the last 6 months
  • Extreme sports during the conduct of the study
  • Pre-existing skin infection at the wearable monitor site
  • Pregnant or lactating woman
  • Participation in another drug or medical device study
  • Inability to give informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (11)

135 rue Nestor Longue Epee

Bersée, 59235, France

NOT YET RECRUITING

203 rue de la Motte

Bersée, 59235, France

RECRUITING

APPT 22 Residence les Tilleuls

Dax, 40100, France

RECRUITING

2 boulevard Winston Churchill

Dijon, 21000., France

NOT YET RECRUITING

2 boulevard Winston Churchill

Dijon, 21000, France

NOT YET RECRUITING

Clinique Lyon Lumiere

Meyzieu, 69330, France

NOT YET RECRUITING

22 rue Jacques Boutrolles

Mont-Saint-Aignan, 76130, France

RECRUITING

19 rue de la Liberté

Nice, 06000, France

NOT YET RECRUITING

119 rue de la Pompe

Paris, 75016, France

RECRUITING

91 rue Caulaincpurt

Paris, 75018, France

RECRUITING

145 avenue des Minimes

Toulouse, 31200, France

NOT YET RECRUITING

MeSH Terms

Conditions

Depressive Disorder, Major

Condition Hierarchy (Ancestors)

Depressive DisorderMood DisordersMental Disorders

Central Study Contacts

Sylvie Lafosse, Pharma D, MBA, INSEAD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 1, 2022

First Posted

September 21, 2022

Study Start

September 5, 2017

Primary Completion

June 30, 2025

Study Completion

June 30, 2025

Last Updated

March 5, 2024

Record last verified: 2024-03

Locations